Literature DB >> 10949907

Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer.

M Koutsilieris1, C Mitsiades, A Sourla.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10949907      PMCID： PMC1949949     

Source DB:  PubMed          Journal:  Mol Med        ISSN： 1076-1551            Impact factor:   6.354


× No keyword cloud information.
  10 in total

Review 1.  The complexity of the IGF1 gene splicing, posttranslational modification and bioactivity.

Authors:  Anastassios Philippou; Maria Maridaki; Spiros Pneumaticos; Michael Koutsilieris
Journal:  Mol Med       Date:  2014-05-07       Impact factor: 6.354

2.  Insulinlike growth factor-1Ec (MGF) expression in eutopic and ectopic endometrium: characterization of the MGF E-peptide actions in vitro.

Authors:  Dimitrios S Milingos; Anastassios Philippou; Athanassios Armakolas; Efstathia Papageorgiou; Antigone Sourla; Athanassios Protopapas; Anthi Liapi; Aris Antsaklis; Minas Mastrominas; Michael Koutsilieris
Journal:  Mol Med       Date:  2010-09-14       Impact factor: 6.354

3.  Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.

Authors:  Vassiliki Poulaki; Constantine S Mitsiades; Vassiliki Kotoula; Sophia Tseleni-Balafouta; Avi Ashkenazi; Demetrios A Koutras; Nicholas Mitsiades
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

4.  IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro.

Authors:  Anastasia Stavropoulou; Antonios Halapas; Antigone Sourla; Anastassios Philippou; Efstathia Papageorgiou; Apostolos Papalois; Michael Koutsilieris
Journal:  Mol Med       Date:  2009-03-06       Impact factor: 6.354

5.  [Somatostatin analogs for the treatment of advanced, hormone-refractory prostate cancer: a possibility for secondary hormonal ablation?].

Authors:  D Schilling; R Küfer; S Kruck; A Stenzl; M A Kuczyk; A S Merseburger
Journal:  Urologe A       Date:  2008-10       Impact factor: 0.639

6.  Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells.

Authors:  Efstathia Papageorgiou; Nea Pitulis; Menelaos Manoussakis; Peter Lembessis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

7.  Suppression of interactions between prostate tumor cell-surface integrin and endothelial ICAM-1 by simvastatin inhibits micrometastasis.

Authors:  Belal Al-Husein; Anna Goc; Payaningal R Somanath
Journal:  J Cell Physiol       Date:  2013-11       Impact factor: 6.384

8.  CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality.

Authors:  Carlo Sorrentino; Luigi D'Antonio; Stefania Livia Ciummo; Cristiano Fieni; Lorena Landuzzi; Francesca Ruzzi; Simone Vespa; Paola Lanuti; Lavinia Vittoria Lotti; Pier Luigi Lollini; Emma Di Carlo
Journal:  J Hematol Oncol       Date:  2022-10-13       Impact factor: 23.168

9.  Evidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate Cancer.

Authors:  Anastassios Philippou; Athanasios Armakolas; Michael Koutsilieris
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-20       Impact factor: 5.555

10.  Immunohistochemical expression of insulin-like growth factor-1Ec in primary endometrial carcinoma: Association with PTEN, p53 and survivin expression.

Authors:  Aggelis Stavropoulos; Michail Varras; Anastassios Philippou; Thivi Vasilakaki; Viktoria-Konstantina Varra; Fani-Niki Varra; Aikaterini Tsavari; Andreas C Lazaris; Michael Koutsilieris
Journal:  Oncol Lett       Date:  2020-10-29       Impact factor: 2.967
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.